Foster Dykema Cabot & Co’s Repligen RGEN Stock Holding History

Foster Dykema Cabot & Co’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-46	Closed	-$7K	–	381
2023 Q2	$7K	Buy	+46	New	+$7.38K	﹤0.01%	280

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Foster Dykema Cabot & Co's RGEN Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Repligen (RGEN) in Q3 2023, closing a stake of 46 shares — an estimated $7K sold.

Foster Dykema Cabot & Co first reported a position in RGEN in Q2 2023 and held it in 1 quarter. The position peaked at $7K in Q2 2023. 439 funds tracked by Wall St. Rank hold RGEN as of Q3 2023.

Foster Dykema Cabot & Co reported no remaining Repligen position as of Q3 2023 after selling out during the quarter.
Foster Dykema Cabot & Co sold 46 Repligen shares in Q3 2023, an estimated $7K.
Foster Dykema Cabot & Co first reported a position in Repligen in Q2 2023 and held it in 1 quarter.
Foster Dykema Cabot & Co's Repligen position peaked at $7K in Q2 2023.
439 funds tracked by Wall St. Rank held Repligen as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.